Alnylam Announces U.S. Food and Drug Administration …
2 days ago · CAMBRIDGE, Mass., November 25, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has ...
Alnylam Shares Surge 30% After Rare Heart Disease Drug Success - Forbes
Jun 24, 2024 · Alnylam said Monday that vutrisiran, an experimental drug for treating a rare condition called transthyretin amyloid cardiomyopathy (ATTR-CM), reduced deaths by all causes and heart-related...
Alnylam Pharmaceuticals Press Release | Nov 25, 2024 | Alnylam ...
2 days ago · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in ...
Press Releases - Alnylam Pharmaceuticals, Inc.
Oct 9, 2024 · Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Sep 29, 2024 Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society ...
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
22 hours ago · Amvuttra sales contribute significantly to Alnylam’s top line. The drug generated sales worth $693.9 million in the nine months ended Sept. 30, 2024, up 79% on a reported basis.
FDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM treatment
2 days ago · Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration or FDA, has accepted for review the Company’s supplemental New Drug Application sNDA for vutrisiran, an ...
Alnylam's drug cuts risk of death, heart issues in key study, shares ...
Jun 24, 2024 · Alnylam Pharmaceuticals said its drug vutrisiran reduced deaths and cardiovascular events by a third in a study involving patients with a rare heart disease, sending the drugmaker's shares...
Alnylam Reports Additional Positive Interim Phase 1 Results for …
Oct 25, 2023 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation...
Alnylam Soars After Drug Meets Goal in Heart Disease Trial - Bloomberg.com
Jun 24, 2024 · A study released Monday found that Alnylam’s vutrisiran, which is sold as Amvuttra, helped patients with a serious heart condition known as known as ATTR amyloidosis with cardiomyopathy.
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial …
Oct 31, 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation ...